Neoplasms

Nervous System Diseases

Gland and Hormone Related Diseases

All Conditions

Rare Diseases

ACTH-Secreting Pituitary Adenoma

Pituitary ACTH Hypersecretion

Adenoma

Pituitary Diseases

Hypothalamic Diseases

Brain Diseases

Central Nervous System Diseases

Endocrine System Diseases

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Pituitary Neoplasms

Endocrine Gland Neoplasms

ACTH-secreting Pituitary Adenoma

Anti-Infective Agents

Antineoplastic Agents

All Drugs and Chemicals

Roscovitine

Antiviral Agents

Protein Kinase Inhibitors

Enzyme Inhibitors

80 mg each day oral seliciclib for 4 weeks

Seliciclib

Vivian Hwe

Shlomo Melmed, MD

Ning-Ai Liu, MD

Ning-Ai Liu, MD, PhD

This phase 2 multicenter, open-label clinical trial will evaluate safety and efficacy of 4 weeks of oral seliciclib in patients with newly diagnosed, persistent, or recurrent Cushing disease.

Funding Source - FDA Office of Orphan Products Development (OOPD)

This phase 2 multicenter, open-label clinical trial will evaluate safety and efficacy of oral seliciclib in patients with newly diagnosed, persistent, or recurrent Cushing disease. Up to 13 subjects will be treated with 80 mg each day for 4 weeks. The study will also evaluate effects of seliciclib on quality of life and clinical signs and symptoms of Cushing disease.

Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease

A Phase 2 Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease

Cedars-Sinai Medical Center

Sr. Vice President of Academic Affairs

Respiratory Tract (Lung and Bronchial) Diseases

Lung Neoplasms

Carcinoma, Non-Small-Cell Lung

Carcinoma

Respiratory Tract Neoplasms

Thoracic Neoplasms

Lung Diseases

Respiratory Tract Diseases

Carcinoma, Bronchogenic

Bronchial Neoplasms

Oral seliciclib at 1200mg b.i.d. for 3 consecutive days as an outpatient beginning on day 1 every 2 weeks for 3 cycles as run-in. Patients (randomized) continue on treatment if derived clinical benefit during run-in period.

Randomized to placebo after run-in period.

seliciclib

placebo

Chandra Belani, M.D.

A phase 2 study to evaluate efficacy of oral seliciclib in treating non-small cell lung cancer (NSCLC).

A randomized Phase II study of an experimental anti-cancer drug called seliciclib with objectives of evaluating safety and efficacy in patients with non-small cell lung cancer.

Efficacy Study of Oral Seliciclib to Treat Non-Small Cell Lung Cancer

A Phase IIb Randomized Study of Oral Seliciclib in Patients With Previously Treated Non-Small Cell Lung Cancer

Time until the disease starts progressing

Cyclacel Pharmaceuticals, Inc.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease	NCT03774446	Cushing Disease	Seliciclib	18 Years -	Cedars-Sinai Medical Center
Efficacy Study of Oral Seliciclib to Treat Non-Small Cell Lung Cancer	NCT00372073	Non-small Cell ...	seliciclib placebo	18 Years -	Cyclacel Pharmaceuticals, Inc.
Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease	NCT03774446	Cushing Disease	Seliciclib	18 Years -	Cedars-Sinai Medical Center

Spots Global Cancer Trial Database for seliciclib

Every month we try and update this database with for seliciclib cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for seliciclib

Every month we try and update this database with for seliciclib cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for seliciclib cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.